|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZYG11A |
Gene summary for ZYG11A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZYG11A | Gene ID | 440590 |
| Gene name | zyg-11 family member A, cell cycle regulator | |
| Gene Alias | ZYG11 | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0000151 | UniProtAcc | Q6WRX3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 440590 | ZYG11A | HCC1 | Human | Liver | HCC | 1.21e-04 | 7.17e-01 | 0.5336 |
| 440590 | ZYG11A | HCC2 | Human | Liver | HCC | 1.76e-07 | 1.06e+00 | 0.5341 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZYG11A | SNV | Missense_Mutation | novel | c.1182G>T | p.Leu394Phe | p.L394F | Q6WRX3 | protein_coding | tolerated(0.06) | possibly_damaging(0.521) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| ZYG11A | SNV | Missense_Mutation | c.758N>A | p.Arg253Lys | p.R253K | Q6WRX3 | protein_coding | tolerated(0.96) | benign(0.013) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ZYG11A | deletion | Frame_Shift_Del | novel | c.1507delA | p.Thr503ArgfsTer15 | p.T503Rfs*15 | Q6WRX3 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZYG11A | SNV | Missense_Mutation | c.1043A>G | p.Glu348Gly | p.E348G | Q6WRX3 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| ZYG11A | SNV | Missense_Mutation | c.2013C>G | p.Phe671Leu | p.F671L | Q6WRX3 | protein_coding | tolerated(0.09) | benign(0.149) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| ZYG11A | SNV | Missense_Mutation | c.2009C>A | p.Ser670Tyr | p.S670Y | Q6WRX3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZYG11A | SNV | Missense_Mutation | c.535N>G | p.Gln179Glu | p.Q179E | Q6WRX3 | protein_coding | tolerated(0.07) | benign(0.063) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZYG11A | SNV | Missense_Mutation | c.772N>G | p.Leu258Val | p.L258V | Q6WRX3 | protein_coding | deleterious(0.02) | probably_damaging(0.965) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZYG11A | SNV | Missense_Mutation | novel | c.814N>C | p.Asp272His | p.D272H | Q6WRX3 | protein_coding | deleterious(0.04) | benign(0.047) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZYG11A | SNV | Missense_Mutation | novel | c.1439N>C | p.Asn480Thr | p.N480T | Q6WRX3 | protein_coding | deleterious(0.01) | benign(0.098) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |